Effects of Anabolic Steroid Use on muscle strength and weight gain in Critically Ill Non-Ventilated Patients. A Randomized Controlled Double Blind Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202408913510687

Enrollment

Registered

2024-08-16

Start date

2024-05-30

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

Sterile water as a Placebo

Intramuscular doses of Decadurabolin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients admitted to ICU for more than 2 weeks, who has significant muscle weakness or weight loss more than 10% due to ICU stay despite participating in physiotherapy program and receiving full nutritional support.

Exclusion criteria

Exclusion criteria: • Intercurrent shock state • Prostate or breast cancer. • Active cardiac condition (EF 5-times normal ranges) • Coagulopathy (INR >1.5 OR Platelets < 50)

Design outcomes

Primary

Measure	Time frame
This study aims to explore potential benefits and safety of administration of anabolic steroid Decadurabolin to critically ill patients having muscle weakness. Primary outcome: to assess Quadriceps femoris muscle thickness (ultrasound guided) four times during time interval of the study	—

Secondary

Measure	Time frame
• Length of ICU stay • ICU mortality • Improvement of muscle weakness • Weight gain • Diaphragmatic muscle thickness	—

Countries

Egypt

Contacts

Public ContactNagwa Mohamed

Assistant lecturer

nagwamohameddoha@yahoo.com00201006235642

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026